Abstract:Aim: Glioma accounts for 81% of all cancers of the nervous system cancers and presents one of the most drug-resistant malignancies, resulting in a relatively high mortality rate. Despite extensive efforts, the complete treatment options for glioma remain elusive. The effect of isocucurbitacin B (isocuB), a natural compound extracted from melon pedicels, on glioma has not been investigated. This study aims to investigate the inhibitory effect of isocuB on glioma and elucidate its underlying mechanisms, with the objective of developing it as a potential therapeutic agent for glioma. Methods: We used network pharmacology and bioinformatics analysis to predict potential targets and associated pathways of isocuB in glioma. Subsequently, the inhibitory effect of isocuB on glioma and its related mechanisms were assessed through Counting Kit-8 (CCK-8), wound healing, transwell, Western blot (WB), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and other in vitro experiments, alongside tumor formation experiments in nude mice. Results: Based on this investigation, it suggested that isocuB might inhibit the growth of gliomas through the PI3K-AKT and MAPK pathways. Additionally, we proposed that isocuB may enhance glioma drug sensitivity to temozolomide (TMZ) via modulation of hsa-mir-1286a. The CCK-8 assay revealed that isocuB exhibited inhibitory effects on U251 and U87 proliferation and outperformed TMZ. Wound healing and transwell experiments showed that isocuB inhibited the invasion and migration of U251 cells by suppressing the activity of MMP-2/9, N-cadherin, and Vimentin. The TdT-mediated dUTP-biotin nick end labeling (TUNEL) and flow cytometry (FCM) assays revealed that isocuB induced cell apoptosis through inhibition of BCL-2. Subsequently, we conducted RT-qPCR and WB experiments, which revealed that PI3K/AKT and MAPK pathways might be involved in the mechanism of the inhibition isocuB on glioma. Additionally, isocuB promoted the sensitivity of glioma U251 to TMZ by inhibiting hsa-mir-1286a. Furthermore, we constructed TMZ-resistant U251 strains and demonstrated effective inhibition by isocuB against these resistant strains. Finally, we confirmed that isocuB can inhibit tumor growth in vivo through experiments on tumors in nude mice. Conclusion: IsocuB may protect against glioma by acting on the PI3K/AKT and MAPK pathways and promote the sensitivity of glioma U251 to TMZ by inhibiting hsa-mir-1286a.

Isoprenylcysteine Carboxyl Methyltransferase is Critical for Glioblastoma Growth and Survival by Activating Ras/Raf/Mek/Erk

PSMC2/E2F1 Axis Promotes the Development and Progression of Glioma

ICMT Contributes to Hepatocellular Carcinoma Growth, Survival, Migration and Chemoresistance Via Multiple Oncogenic Pathways.

TMBIM1 Promotes EMT by Stimulating Autophagic Degradation of E-cadherin Via AMPK/mTOR/ULK1 Axis in Human Gliomas

Inhibition of Isoprenylcysteine Carboxylmethyltransferase Sensitizes Common Chemotherapies in Cervical Cancer Via Ras-dependent Pathway.

Isoprenylcysteine carboxyl methyltransferase (ICMT) promotes invadopodia formation and metastasis in cancer cells

CMTM6 Knockdown Prevents Glioma Progression by Inactivating the Mtor Pathway

Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a

Isoprenylcysteine carboxyl methyltransferase promotes the progression of tongue squamous cell carcinoma via the K-Ras and RhoA signaling pathways

Tmic-76. Prmt5 Modulates T Cell Proliferation In Glioblastoma Tumor Microenvironment

Monocarboxylate transporter dependent mechanism is involved in proliferation, migration, and invasion of human glioblastoma cell lines via activation of PI3K/Akt signaling pathway

Csig-25. Mapk/Erk Signaling In Gliomas Modulates Interferon Responses, Promotes Tumor-Microglia Crosstalk, And Confers Susceptibility To Anti-Pd-1 And Anti-Ctla-4 Immunotherapy

Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy

PSMC2 Promotes Glioma Progression by Regulating Immune Microenvironment and PI3K/AKT/mTOR Pathway

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

TMET-10. TARGETING PGM3 TO INHIBIT HEXOSAMINE PRODUCTION IS AN EFFECTIVE APPROACH TO TREAT GLIOBLASTOMA

Mammalian Target Of Rapamycin Signaling Pathway Contributes To Glioma Progression And Patients' Prognosis

MicroRNA-873 (MiRNA-873) Inhibits Glioblastoma Tumorigenesis and Metastasis by Suppressing the Expression of IGF2BP1

Methionine regulates self-renewal, pluripotency, and cell death of GIC through cholesterol-rRNA axis

Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation.

Tmet-35. Upregulation Of The Uridine Salvage Pathway In Mesenchymal Glioblastoma Stem-Like Cells